Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

tivozaniv

- PMLiVE

Merck’s Welireg granted EC approval for von Hippel-Lindau disease and kidney cancer

Up to 15,000 people in Europe are living with VHL, a rare tumour-causing genetic disease

- PMLiVE

Merck shares positive results for Keytruda in phase 3 kidney cancer study

Renal cell carcinoma accounts for approximately 90% of all kidney cancer diagnoses

- PMLiVE

Bristol Myers Squibb’s subcutaneous Opdivo shows promise in kidney cancer

More than 430,000 new cases of renal cell carcinoma are diagnosed globally every year

- PMLiVE

BMS, Exelixis and Ipsen announce positive four-year results for kidney cancer regimen

More than 430,000 new cases of renal cell carcinoma are diagnosed globally every year

- PMLiVE

Johnson & Johnson to acquire ADC specialist Ambrx Biopharma for approximately $2bn

The deal includes an ADC candidate in clinical development to treat advanced prostate cancer

- PMLiVE

Merck shares positive results for adjuvant Keytruda in phase 3 kidney cancer trial

Renal cell carcinoma accounts for approximately 90% of all kidney cancer diagnoses

- PMLiVE

Merck shares positive late-stage results for Welireg in advanced kidney cancer

Renal cell carcinoma accounts for approximately 90% of kidney cancer diagnoses

- PMLiVE

BMS, Exelixis and Ipsen report three-year results for combination treatment in kidney cancer

Renal cell carcinoma accounts for more than 431,000 new cases and 179,000 deaths each year

- PMLiVE

Merck bags NICE recommendation for renal cell carcinoma adjuvant treatment

Patients will now be able to access immunotherapy at an earlier stage in their treatment pathway

- PMLiVE

Merck & Co announces results at ASCO for Keytruda plus Lenvima for kidney cancer patients

Renal cell carcinoma is the most common form of kidney cancer

- PMLiVE

European Commission approves Opdivo plus Cambometyx for advanced kidney cancer

Checkpoint inhibitor plus tyrosine kinase inhibitor approved for the first-line treatment of advanced renal cell carcinoma

- PMLiVE

New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer

Data presented at the virtual American Society of Clinical Oncology’s Genitourinary Cancers Symposium

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links